Rockefeller Capital Management
CAPR icon

Rockefeller Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Rockefeller Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.21K Buy
270
+177
+190% +$4.72K ﹤0.01% 4074
2025
Q4 		$2.68K Hold
93
– – ﹤0.01% 4243
2025
Q3 		$671 Buy
+93
New +$685 ﹤0.01% 4233

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Rockefeller Capital Management's CAPR Position: Q1 2026 in Review

Rockefeller Capital Management increased its Capricor Therapeutics (CAPR) stake by 190% in Q1 2026, buying an estimated $4.72K and bringing the position to 270 shares worth $8.21K. The position accounts for ﹤0.01% of the portfolio, ranked #4074.

Rockefeller Capital Management first reported a position in CAPR in Q3 2025 and has held it in 3 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Rockefeller Capital Management held 270 shares of Capricor Therapeutics worth $8.21K as of Q1 2026.
  • Rockefeller Capital Management bought 177 Capricor Therapeutics shares in Q1 2026, an estimated $4.72K.
  • Capricor Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4074 holding.
  • Rockefeller Capital Management first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.